Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Confirmed Bundibugyo ebolavirus infections reached 1,708 with 580 deaths, increasing from early July counts and prompting WHO’s May 17 PHEIC designation. Unpaid wages and bonuses since mid-May ...

Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions. On the selection side, Rogers explains why covalent ...

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...

In a recent podcast, Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, offered a candid account ...

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care. In part 2 of an interview with The American ...

Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...

ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...

Pediatric cancer hospitalizations are approximately 2.5 times costlier than adult admissions, reflecting longer stays and ...